Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer.

Content Provider	Europe PMC
Author	Grimaldo-Roque, Hiram Josue Martinez-Castaneda, Erika Adriana Morales-Garcia, Mariana G. Leal-Hidalgo, Jorge Luis Torres-Guillen, Valeria M. Dorantes-Heredia, Rita Motola-Kuba, Daniel Ruiz-Morales, Jose Manuel
Copyright Year	2022
Abstract	BackgroundIn Mexico, about 30% of renal cancer patients are diagnosed in a metastatic state. Despite the recent advances in the treatment of cancer, metastatic renal cancer is still an incurable illness. Thus, identifying prognostic factors helps improve prognosis accuracy and survival prediction for patients.MethodsIn this study, we retrospectively analyzed 26 patients with histological diagnosis of renal cell carcinoma, including clear cell and other subtypes in stage IV (metastatic), recurrent or unresectable disease. We performed a multivariate analysis of overall survival regarding the congruity between prognostic scales.ResultsOur results showed a significant difference in favor of patients with congruity between scales for progression-free survival (18.9 vs. 3.1 months; P = 0.048) and a tendency towards better overall survival in patients with the congruity of both scales compared to the discordant patients (112 vs. 32 months; P = 0.99).ConclusionThis study highlights the discordance between Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium scales, which was associated with worse prognosis with a significant difference in progression-free survival but not in overall survival.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9076149&blobtype=pdf
ISSN	19204531
Journal	World Journal of Oncology [World J Oncol]
Volume Number	13
DOI	10.14740/wjon1400
PubMed Central reference number	PMC9076149
Issue Number	2
PubMed reference number	35571342
e-ISSN	1920454X
Language	English
Publisher	Elmer Press
Publisher Date	2022-04-23
Access Restriction	Open
Rights License	This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright 2022, Grimaldo-Roque et al.
Subject Keyword	Prognosis Renal cell cancer Targeted therapy
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology